neostigmine methylsulfate，raceanisodamine hydrochloride
Small molecule
neostigmine methylsulfate，raceanisodamine hydrochloride is one of 9 small molecule programs targeting Jaundice. It is currently in development.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
11 competitors in Jaundice
#DrugCompanyPhaseTrials
1Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Decadron
AAspen Global Incorporated
Phase 3
Cysteine Hydrochloride
NovartisPhase 2
Remaxol
PPOLYSAN Scientific & Technological Pharmaceutical Company
Phase 3
Stannsoporfin
IInfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Phase 2
Verazinc
FFakultas Kedokteran Universitas Indonesia
Preclinical
Rocephin
CConrado Roberto Hoffmann Filho
Preclinical
Glycerin
CCalm Water Therapeutics LLC
Preclinical
neostigmine methylsulfate，raceanisodamine hydrochloride
WWanqing Gu
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- WWanqing Gu